DK1066376T3 - Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner - Google Patents

Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner

Info

Publication number
DK1066376T3
DK1066376T3 DK99911949T DK99911949T DK1066376T3 DK 1066376 T3 DK1066376 T3 DK 1066376T3 DK 99911949 T DK99911949 T DK 99911949T DK 99911949 T DK99911949 T DK 99911949T DK 1066376 T3 DK1066376 T3 DK 1066376T3
Authority
DK
Denmark
Prior art keywords
ompf
aroc
mutation
vaccines
reversing
Prior art date
Application number
DK99911949T
Other languages
Danish (da)
English (en)
Inventor
Steven Neville Chatfield
Original Assignee
Acambis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Res Ltd filed Critical Acambis Res Ltd
Application granted granted Critical
Publication of DK1066376T3 publication Critical patent/DK1066376T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
DK99911949T 1998-03-25 1999-03-25 Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner DK1066376T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9806449.6A GB9806449D0 (en) 1998-03-25 1998-03-25 Attenuated bacteria useful in vaccines
PCT/GB1999/000935 WO1999049026A1 (fr) 1998-03-25 1999-03-25 Bacteries attenuees par mutation irreversible de chacun des genes aroc, ompf et ompc, utiles dans des vaccins
EP99911949A EP1066376B1 (fr) 1998-03-25 1999-03-25 Bacteries attenuees par mutation irreversible de chacun des genes aroc, ompf et ompc, utiles dans des vaccins

Publications (1)

Publication Number Publication Date
DK1066376T3 true DK1066376T3 (da) 2005-10-03

Family

ID=10829280

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99911949T DK1066376T3 (da) 1998-03-25 1999-03-25 Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner

Country Status (19)

Country Link
US (1) US6902906B1 (fr)
EP (1) EP1066376B1 (fr)
JP (1) JP4516210B2 (fr)
KR (1) KR100628657B1 (fr)
AT (1) ATE296881T1 (fr)
AU (1) AU763683B2 (fr)
CA (1) CA2323576C (fr)
CZ (1) CZ301520B6 (fr)
DE (1) DE69925585T2 (fr)
DK (1) DK1066376T3 (fr)
ES (1) ES2244182T3 (fr)
GB (1) GB9806449D0 (fr)
HU (1) HU225644B1 (fr)
NO (1) NO327609B1 (fr)
NZ (1) NZ507077A (fr)
PL (1) PL196076B1 (fr)
PT (1) PT1066376E (fr)
WO (1) WO1999049026A1 (fr)
ZA (1) ZA200004987B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
EP1352245B1 (fr) * 2001-01-18 2006-08-16 Newcastle University Ventures Limited Biocapteur a proteines transmembranaires attachees de maniere covalente
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
EP1981536A4 (fr) * 2006-02-01 2012-03-14 Gotovax Ab Antigenes de facteur de colonisation d'escherichia coli enterotoxigenes dans des bacteries recombinees
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
PT2066339E (pt) 2006-09-18 2014-10-31 Texas A & M Univ Sys Composições e métodos de potenciar respostas imunes
JP2011502165A (ja) * 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
WO2014037445A1 (fr) * 2012-09-05 2014-03-13 Lohmann Animal Health Gmbh Préparation de vaccins vivants
PL3415643T3 (pl) * 2012-09-05 2020-06-01 Lohmann Animal Health Gmbh Wytwarzanie żywych szczepionek
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
CA2906079C (fr) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions et procedes pour ameliorer les reactions immunitaires aux pathogenes enteriques
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
ATE111957T1 (de) * 1990-02-06 1994-10-15 Pasteur Institut Transformiertes shigella.
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
DK0574466T3 (da) * 1991-03-05 1999-11-08 Wellcome Found Udtrykkelse af rekombinante proteiner i svækkede bakterier

Also Published As

Publication number Publication date
KR100628657B1 (ko) 2006-09-26
AU763683B2 (en) 2003-07-31
AU3045899A (en) 1999-10-18
CZ20003470A3 (cs) 2001-07-11
HUP0105430A2 (hu) 2002-04-29
CA2323576C (fr) 2010-12-07
ZA200004987B (en) 2001-10-31
HUP0105430A3 (en) 2004-10-28
KR20010042175A (ko) 2001-05-25
HU225644B1 (en) 2007-05-02
DE69925585D1 (de) 2005-07-07
CA2323576A1 (fr) 1999-09-30
ES2244182T3 (es) 2005-12-01
JP4516210B2 (ja) 2010-08-04
US6902906B1 (en) 2005-06-07
GB9806449D0 (en) 1998-05-27
EP1066376A1 (fr) 2001-01-10
DE69925585T2 (de) 2006-07-13
NO327609B1 (no) 2009-08-31
PL196076B1 (pl) 2007-12-31
NO20004781D0 (no) 2000-09-25
EP1066376B1 (fr) 2005-06-01
NO20004781L (no) 2000-11-08
ATE296881T1 (de) 2005-06-15
CZ301520B6 (cs) 2010-03-31
JP2002507414A (ja) 2002-03-12
NZ507077A (en) 2002-10-25
PT1066376E (pt) 2005-10-31
WO1999049026A1 (fr) 1999-09-30
PL343246A1 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
DK1066376T3 (da) Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner
Brown et al. MlrA, a novel regulator of curli (AgF) and extracellular matrix synthesis by Escherichia coli and Salmonella enterica serovar Typhimurium
Oyston et al. The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis
Pukatzki et al. Identification of a conserved bacterial protein secretion system in Vibrio cholerae using the Dictyostelium host model system
Balsanelli et al. Herbaspirillum seropedicae rfbB and rfbC genes are required for maize colonization
WO1998056901A3 (fr) Vaccin vivant attenue
KR937000640A (ko) 생 백신
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
CY1110995T1 (el) Ασφαλη μεταλλακτικα ιικα εμβολια
CY1107950T1 (el) Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
DE60207277D1 (de) Bakterieller impfstoff
Zogaj et al. Characterization of the Francisella tularensis subsp. novicida type IV pilus
Andoh et al. Comparative virulence of phase I and II Coxiella burnetii in immunodeficient mice
WO2000003003A3 (fr) Criblage de candidats-vaccins antineisseria et vaccins contre une neisseria pathogene
Meyer et al. Virulence of a Salmonella typhimurium OmpD mutant
Seshadri et al. Genome analysis of Coxiella burnetii species: insights into pathogenesis and evolution and implications for biodefense
Li et al. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live meningococci
HUP9702355A2 (hu) Avirulens Mycoplasma synoviae, és az ezt tartalmazó vakcina
Krueger et al. Unravelling post‐transcriptional PrmC‐dependent regulatory mechanisms in Pseudomonas aeruginosa
NO20020665L (no) Streptomyces Avermitilis gen som bestemmer forholdet B2:B1 avermectiner
BR0013119A (pt) Gene de streptomyces avermitilis que regula a proporção de avermectinas b2:bl
BR9809974A (pt) Vacinas vivas atenuadas
WO2004089408A3 (fr) Preparations de vaccins
WO2002081676A3 (fr) Souche bacterienne non pathogene d'une bacterie contenant de l'acide mycolique, son procede de production et son utilisation
HUP9800094A2 (hu) Nem patogén mutáns E. coli törzsek, előállításuk és alkalmazásuk